Welcome to LiVDerm
Where the Constellations of Medical Dermatology and Aesthetics Collide
Led by world-renowned experts in the field, LiVDerm is a comprehensive dermatologic hub where medical professionals educate, collaborate, and engage.
LiVDerm’s mission is to boldly advance higher standards of dermatology care through live and virtual educational offerings, resources for providers, students and patients, and much more.
As a leading source for the latest therapies, technologies, procedures, and practice guidelines in medical and aesthetic dermatology, LiVDerm empowers providers to manage dermatologic conditions with confident authority. With a multipronged focus on the myriad specialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.
Upcoming Live Events
Complimentary Continuing Education
Chronic Urticaria
Interactive Monograph
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria Beyond Skin Deep
Atopic Dermatitis
Enduring Webcast
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis
Seborrheic Dermatitis
Enduring Webcast
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
LivDerm Articles
FDA Approves Vtama for Atopic Dermatitis for Patients Two Years and Above
Organon has announced the recent approval of Vtama ® (tapinarof) cream 1% for atopic dermatitis (AD) in adults and children aged 2 years and older. Vtama,…
Study Finds Ultraprocessed Foods Linked to Active Psoriasis
Diet, which plays a critical role in reducing inflammation and improving quality of life, has emerged as a significant factor in managing inflammatory diseases. Concerns,…
Study Highlights Safety and Efficacy of Monopolar Radiofrequency and HIFES in Patients Receiving Botulinum Toxin
A recent study published in the Journal of Drugs in Dermatology evaluated the safety and efficacy of a novel device combining monopolar radiofrequency (RF) and…
FDA Approves BIMZELX for Moderate-to-Severe Hidradenitis Suppurativa
UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in…
New Protection and Repair Skincare Regimen Improves Photoaging
A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen,…
Study Evaluates Relationship Between Hidradenitis Suppurativa and Precocious Puberty
A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from…
FDA Grants Rare Pediatric Disease Designation for BPGbio’s BPM31510T for EB
The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news…
Study Finds Newly Diagnosed Alopecia Areata Linked to Increased Risk of Psychiatric and Autoimmune Conditions
A recent study published in the Journal of the American Medical Association (JAMA Dermatology) found that patients with newly diagnosed alopecia areata (AA) have a…
FDA Approves BOTOX® Cosmetic for Platysma Bands in Adults
Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands…
Topical Corticosteroid Phobia is Prevalent Among Patients with Chronic Hand Eczema
A study conducted in patients with chronic hand eczema (CHE) revealed that topical corticosteroid (TCS) phobia is a great concern, with many fearing future health…
Study Underway to Evaluate Rezpegaldesleukin (REZPEG) for the Treatment of Alopecia Areata
A new phase 2b study is currently underway to evaluate rezpegaldesleukin (REZPEG), an interleukin-2 receptor pathway agonist, for the treatment of severe to very severe alopecia…
Semaglutide Demonstrates Potential in Improving Outcomes for Hidradenitis Suppurativa in Patients with Obesity
In a study recently presented at the European Academy of Dermatology and Venerology (EADV) Congress 2024, it was revealed that semaglutide has the potential to…
Arcutis Announces FDA has Accepted its Supplemental New Drug Application for ZORYVE® (roflumilast) Foam
In a press release from Arcutis Biotherapeutics, Inc., they have announced that the U.S. Food and Drug Administration (FDA) has accepted its sNDA for ZORYVE…
Eli Lilly’s EBGLYSS Receives FDA Approval for Patients 12 and Above with Moderate-to-Severe Atopic Dermatitis
Eli Lilly has announced that EBGLYSS ™ (lebrikizumab-lbkz) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic…
AHEAD Recommendations for Atopic Dermatitis
A team of expert dermatologists recently drafted recommendations for managing atopic dermatitis (AD) to optimize treatment outcomes. They noted that current treat-to-target recommendations for AD…
National Psoriasis Foundation Publishes Psoriasis Health Indicator Report
The National Psoriasis Foundation has released a Psoriasis Health Indicator Report detailing the health impacts of psoriasis. The report includes information and data on psoriasis,…
FDA Warns Consumers Against Using Chemical Peel Products Without Professional Consultation
The U.S. Food and Drug Administration (FDA) has warned consumers against the purchase and use of certain chemical peel skin products without first consulting a…
FDA Approves Galderma’s Nemluvio® (nemolizumab) for Prurigo Nodularis in Adults
The U.S. Food and Drug Administration (FDA) has approved Galderma’s Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of prurigo nodularis in…
Skin Deep: Dr. Zoe Diana Draelos Explores Ethnic Variations in Skin Physiology - Dermatology Times Exclusive
In a recent article published in the Dermatology Times, Zoe Diana Draelos, MD, addressed some of the complex issues surrounding the physiologic differences in skin…
Omega-3 Fatty Acid Supplementation May Help Alleviate Acne Severity
According to a recent study, increasing the intake of omega-3 fatty acids through dietary intervention and supplementation may alleviate acne severity. Over a 16-week period,…
LivDerm Podcasts
IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis
Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?
Exploring the Latest Updates in the Epidermolysis Bullosa Treatment Landscape
Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management
Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis
Skirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term Control
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?
Skirting Steroids in Atopic Dermatitis: Dangers and Side Effects of Steroid Exposure in Treatment of AD
Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy
The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence
Targeted Intervention for Hidradenitis Suppurativa: Defining Window of Opportunity for Moderate-to-Severe Patients
Psoriasis in Skin of Color Unplugged: Patient and Disease Advocacy
Psoriasis in Skin of Color Unplugged: Advancing Diversity and Inclusion in Clinical Trials
Psoriasis in Skin of Color Unplugged: Gaps in Diagnosis and Dermatologist Training
Psoriasis in Skin of Color Unplugged: Disparities and Access to Care
The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors
Updates in JAK Inhibitor Therapies for Alopecia Areata with Brett King, MD
Nuanced Treatment of Pediatric Alopecia Areata with Brittany Craiglow, MD
Navigating the Expanding Treatment Landscape for Pediatric Patients with Atopic Dermatitis
Pearls for Early and Accurate Diagnosis of Infantile Atopic Dermatitis
Improving Communication and Shared Decision-Making with Caregivers of Patients with Atopic Dermatitis
The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis
The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis
Dermatologic Care in the Sexual and Gender Diverse Patient with Klint Peebles, MD
The Latest Advances in Cosmetic Dermatology with Doris J. Day, MD
The Latest Advances with Energy-Based Devices and Scar Treatments with Michael H. Gold, MD, FAAD
Anatomy Matters: The Cadaver Lab Experience with Z. Paul Lorenc, MD
Finding the Fountain of Youth: How Light Keeps Your Skin Glowing
Connect With Us
Looking for more information on our educational opportunities? Please fill out the form below to be contacted by one of our education advisors.
